Alteogen to Present Subcutaneous ADC Formulation Research at International Forum in June
Alteogen announced on the 23rd that it will present research results regarding subcutaneous dosing for antibody-drug conjugate therapies at the...
Search results for "antibody-drug conjugate"
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous injections to subcutaneous...
Datroway Approved: New Targeted Therapy Offers Hope for Metastatic Breast Cancer
A new therapeutic horizon has arrived for patients battling metastatic breast cancer that has progressed despite...
FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate
Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug...
A Ray of Hope: ‘Low Expression’ Changes the Landscape of Breast Cancer Treatment
The treatment landscape for metastatic breast cancer is undergoing a significant shift.
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval
South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
LigaChemBio Receives Milestone from Czech Sotio Biotech
LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product...
Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears
Among breast cancers, ‘triple-negative breast cancer ’ is particularly challenging to treat.
Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical
Ligakem Bioscience announced on the 8th that it is set to receive milestone payments related to the development...
Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals
Ligand Pharmaceuticals announced on the 5th that it has recruited Dr. Han Jin-hwan, formerly of Merck, as the head of...